Day: July 5, 2012

Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

Weston, Mass and Stockholm, Sweden – July 5, 2012 – Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum (STO:SOBI) today announced the initiation of two global pediatric clinical trials of the companies’ long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in hemophilia A and B.rFVIIIFc and rFIXFc are fully-recombinant clotting factors […]